>
Innovating Value Chains

Deeplife

DeepLife is a Paris-based biotech innovator transforming drug discovery at the cellular level. Founded in 2019 by CEO Jonathan Baptista and CTO Jean‑Baptiste Morlot, the company has developed the first SaaS platform for creating “digital twins” of individual cells. By combining multi-omics data, causal AI, and systems engineering, DeepLife simulates cellular behaviour to rapidly identify molecular triggers that can revert diseased cells to a healthy state—dramatically reducing target discovery timelines from years to months and increasing research success rates from the industry‑standard 0.01%

Details

Headquarters

France

Current Stage

Series A

Backed by YZR

Co-Investors

Turenne Groupe, kima ventures

News

Updates
December 11, 2024

Sifted: French GenAI drug discovery startup DeepLife raises $10m as it mulls US relocation

Read Article